Exagen, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30068X1037
USD
2.88
0.03 (1.05%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
GeneDx Holdings Corp.
Exagen, Inc.
Sonida Senior Living, Inc.
Dyadic International, Inc.
Personalis, Inc.
Cano Health, Inc.
Sera Prognostics, Inc.
IMAC Holdings, Inc.
Novo Integrated Sciences, Inc.
Biora Therapeutics, Inc.
EUDA Health Holdings Ltd.

Why is Exagen, Inc. ?

1
Poor long term growth as Operating profit has grown by an annual rate 3.42% of over the last 5 years
2
Flat results in Sep 25
  • ROCE(HY) Lowest at -122.81%
  • INTEREST(Q) Highest at USD 1.32 MM
  • EPS(Q) Lowest at USD -0.31
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -32.35%, its profits have risen by 7.6%
4
Below par performance in long term as well as near term
  • Along with generating -32.35% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Exagen, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Exagen, Inc.
-28.89%
0.58
65.07%
S&P 500
13.68%
0.71
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
9.98%
EBIT Growth (5y)
3.42%
EBIT to Interest (avg)
-9.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.70
Sales to Capital Employed (avg)
1.42
Tax Ratio
0.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
59.51%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.19
EV to EBIT
-5.26
EV to EBITDA
-6.22
EV to Capital Employed
8.46
EV to Sales
1.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-160.94%
ROE (Latest)
-86.21%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
NET PROFIT(HY)

Higher at USD -8.12 MM

NET SALES(Q)

Highest at USD 17.24 MM

RAW MATERIAL COST(Y)

Fallen by -4.76% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -41.27 %

DEBTORS TURNOVER RATIO(HY)

Highest at 6.21 times

-13What is not working for the Company
ROCE(HY)

Lowest at -122.81%

INTEREST(Q)

Highest at USD 1.32 MM

EPS(Q)

Lowest at USD -0.31

Here's what is working for Exagen, Inc.

Net Sales
Highest at USD 17.24 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Net Profit
Higher at USD -8.12 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Sales
At USD 17.24 MM has Grown at 17.18%
over average net sales of the previous four periods of USD 14.72 MM
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Debt-Equity Ratio
Lowest at -41.27 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 6.21 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -4.76% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Exagen, Inc.

Interest
At USD 1.32 MM has Grown at 17.35%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest
Highest at USD 1.32 MM
in the last five periods and Increased by 17.35% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

EPS
Lowest at USD -0.31
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)